Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Seizures 2Glioma 2Epilepsy 1Drug Resistant Epilepsy 1Brain Neoplasms 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × perampanel × CNS × Clear all
NCT04497142 2024-08-05

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Dana-Farber Cancer Institute

Phase 1/2 Completed
12 enrolled 8 charts
CNS

Glioma, Seizures

NCT04650204 2023-06-22

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Mayo Clinic

Phase 4 Terminated
4 enrolled 9 charts
CNS

Drug Resistant Epilepsy, Epilepsy, Glioma

NCT02363933 2018-04-27

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Duke University

Phase 4 Completed
9 enrolled 9 charts
CNS

Brain Neoplasms, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon âš¡